

Iskra Pusic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8006957/publications.pdf>

Version: 2024-02-01

53
papers

3,873
citations

257450

24
h-index

243625

44
g-index

55
all docs

55
docs citations

55
times ranked

5922
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	2.2	213
2	Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD. <i>Bone Marrow Transplantation</i> , 2022, 57, 302-303.	2.4	1
3	Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. <i>Blood</i> , 2022, 139, 1177-1183.	1.4	41
4	Germinal centre-driven maturation of B cell response to mRNA vaccination. <i>Nature</i> , 2022, 604, 141-145.	27.8	198
5	Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. <i>Haematologica</i> , 2022, 107, 1709-1713.	3.5	2
6	A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease. <i>Blood</i> , 2021, 137, 896-907.	1.4	15
7	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	1.2	24
8	SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. <i>Nature</i> , 2021, 595, 421-425.	27.8	428
9	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021, 138, 2278-2289.	1.4	124
10	Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease. <i>British Journal of Haematology</i> , 2021, 195, 306-307.	2.5	0
11	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	1.2	65
12	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. <i>Leukemia Research</i> , 2021, 110, 106713.	0.8	9
13	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. <i>JCO Precision Oncology</i> , 2021, 5, 191-203.	3.0	4
14	Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3904-3904.	1.4	0
15	The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 589-592.	4.7	22
16	Cardio-Oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 480-504.	329.8	29
17	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. <i>Cancer Discovery</i> , 2020, 10, 1854-1871.	9.4	83
18	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e404-e407.	3.5	16

#	ARTICLE	IF	CITATIONS
19	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	41
20	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , 2020, 135, 97-107.	1.4	56
21	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. <i>Blood Advances</i> , 2020, 4, 40-46.	5.2	11
22	Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1612-1619.	2.0	12
23	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2002-2007. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.0	64
24	methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>Lancet Haematology</i> , 2019, 6, e132-e143.	4.6	200
25	Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. <i>Blood</i> , 2019, 134, 3915-3915.	1.4	6
26	Challenges in Conducting Studies in Chronic Graft-versus-Host Disease. <i>Clinical Hematology International</i> , 2019, 1, 36.	1.7	5
27	Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018, 53, 826-831.	2.4	69
28	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 1028-1041.	27.0	93
29	Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. <i>JCI Insight</i> , 2018, 3, .	5.0	48
30	Investigating the Effects of Clonal Hematopoiesis in Healthy Marrow and Blood Donors on the Outcomes of Recipients Following Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 2180-2180.	1.4	0
31	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250.	1.4	352
32	Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. <i>Blood</i> , 2017, 130, 816-816.	1.4	7
33	Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1137-1141.	2.0	11
34	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2016, 49, 1-6.	0.8	31
35	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	27.0	663
36	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113

#	ARTICLE	IF	CITATIONS
37	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 728-730.	1.3	14
38	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	7.0	68
39	Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. <i>Blood</i> , 2016, 128, LBA-3-LBA-3.	1.4	12
40	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1761-1769.	2.0	143
41	A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results. <i>Blood</i> , 2015, 126, 1935-1935.	1.4	2
42	Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. <i>Blood</i> , 2015, 126, 1950-1950.	1.4	5
43	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. <i>Blood</i> , 2015, 126, 689-689.	1.4	1
44	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 3144-3144.	1.4	0
45	Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 46-52.	2.0	86
46	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 2456-2456.	1.4	1
47	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 5292-5292.	1.4	0
48	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 850-850.	1.4	0
49	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. <i>Blood</i> , 2013, 122, 3931-3931.	1.4	0
50	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. <i>Blood</i> , 2013, 122, 2816-2816.	1.4	0
51	Update on clinical experience with AMD3100, an SDF-1/CXCL12â€“CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. <i>Current Opinion in Hematology</i> , 2010, 17, 319-326.	2.5	124
52	Phase-2 Study of Pomalidomide in Advanced Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD).. <i>Blood</i> , 2009, 114, 3326-3326.	1.4	2
53	Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1045-1056.	2.0	319